HEMGENIX - AN OVERVIEW

Number of suitable people: CDEC discussed the uncertainty in the number of patients with moderately severe to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some people who're classified as having moderate or reasonable ailment could have a extreme bleeding phen